Detecting Gynecologic Cancers Using Vaginal Fluid and Blood Markers

Trial details

Who runs it

Mayo Clinic

Trial code

NCT05051722

Record updated

5 November 2026

Original description

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.Read full original descriptionShow less

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer: a Phase II Clinical Study

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma.

This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid. Additionally, it defines necessary Phase I MDM-based cancer detection and exploratory aims to test novel cervical cancer (CC) MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.er detection and exploratory aims to test novel cervical cancer MDMs and test the specificity of cancer-specific MDMs among various common benign gynecologic pathologies.

Inclusion: Patients will be ≥45 years of age and meet one of the following criteria:; Abnormal uterine bleeding; Postmenopausal bleeding; OR; Patients ages 18 - 44 years of age and meet these criteria; Abnormal uterine bleeding; One risk factor for endometrial cancer (BMI ≥30 or PCOS or Tamoxifen use); Patients will be ≥18 years of age and meet at least one of the following criteria:; Presence of biopsy-proven EC (any histology, including uterine carcinosarcoma) and surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D\&C, hysteroscopic resection; Biopsy showing AEH or EIN with surgical intervention planned. Surgical intervention can include any of the following: hysterectomy, D\&C, hysteroscopic resection, etc); Patients will be ≥18 years of age, have a cervix and meet at least one of the following criteria:; History of current abnormal cervical/endocervical Pap test for which the patient is presenting for colposcopy; Cervical mass identified on physical exam and patient referred for cervical biopsy, even if colposcopy not recommended or indicated; Planned clinically indicated surgical excisional biopsy or removal of the cervix (cold knife cone, LEEP, hysterectomy) for abnormal Pap test, cervical dysplasia, cervical mass, or biopsy-proven invasive cervical cancer (adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or less common primary cervical carcinomas all eligible); Patients will be ≥45 years of age and should meet at least one of the following criteria:; Undergoing hysterectomy with biopsy-proven or clinically presumed (based on imaging and/or clinical symptoms) benign gynecologic or uterine pathology of fibroids, endometriosis, adenomyosis, or benign endometrial polyps; Undergoing any gynecologic surgery in which a benign pathologic tissue diagnosis of fibroids, endometriosis, adenomyosis, or benign endometrial polyp is anticipated to be confirmed; Patients with a uterus will be ≥45 years of age and should meet the following criteria:; Presenting for GYN wellness exam, ± Pap test; No change in medical conditions, new diagnoses, or new medications within the past 6 months; Patients ≥50 years of age and:; Postmenopausal; At least 1 intact ovary; Diagnosis of an adnexal mass or a clinical suspicion of early-stage ovarian cancer (including fallopian tube cancer); Planned surgery for the adnexal mass; For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion); Women will be ≥18 years of age and meet the following criteria:; Presence of clinically probable ovarian, fallopian tube, or primary peritoneal cancer (all under the umbrella of OC) based on clinical findings of any/all of the following: imaging showing adnexal and/or abdominal masses consistent with probable ovarian cancer, omental caking, elevated CA125, ascites, imaging-guided biopsy consistent with OC pathology; Newly diagnosed with ovarian, fallopian tube or primary peritoneal cancer without neoadjuvant therapy; At least one intact ovary; For vaginal fluid collection, patient must have a uterus, cervix and at least 1 intact fallopian tube* (without prior tubal ligation/occlusion).

Exclusion: Prior hysterectomy; Any prior pelvic or vaginal radiotherapy; Chemotherapy within the past 5 years; Undergoing surgical procedure for recurrent or metastatic EC; Received preoperative neoadjuvant chemotherapy or radiotherapy for current EC diagnosis; Prior hysterectomy; Prior or current biopsy-proven cervical cancer; Presence of concomitant biopsy-proven cervical dysplasia; Any prior pelvic or vaginal radiotherapy; Chemotherapy within the past 5 years; Prior intervention or surgery with intent to completely remove the target pathology; Prior total hysterectomy (cervix removed) for any indication; Chemotherapy within the past 5 years; Patients presenting for colposcopy as part of lower genital tract dysplasia or cancer surveillance after prior curative intent treatment and no current Pap abnormality or cervical mass; Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode; Endometrial biopsy or office hysteroscopy within 2 weeks preceding the planned gynecologic surgery procedure for fibroids, endometriosis, benign endometrial polyps, or adenomyosis; Any surgery within the past 3 months; Prior hysterectomy; Prior or current biopsy-proven gynecologic cancer; Prior pelvic or vaginal radiotherapy; Chemotherapy within the past 5 years; Prior intervention or surgery with intent to completely remove the target pathology for the current lesion / diagnosis during the current episode; Any surgery within the past 3 months; Prior hysterectomy; Prior or current biopsy-proven gynecologic cancer; Prior pelvic or vaginal radiotherapy; Chemotherapy within the past 5 years; Chemotherapy for cancer treatment within the past 5 years prior to collection; Clinically suspected advanced stage ovarian cancer (Stage III or IV) on presentation, if known prior to specimen collection; Chemotherapy for cancer treatment within the past 5 years prior to collection; Any prior cancer (except basal cell skin cancer) within the past 5 years; Current biopsy-proven cervical, vaginal, or vulvar cancer or lower genital tract dysplasia; Current biopsy-proven endometrial cancer or endometrial hyperplasia; Any prior cancer (except basal cell skin cancer) within the past 5 years; History of pelvic or vaginal radiotherapy; Cervical mass biopsy-proven to be EC or a cancer metastatic from a non-cervical origin; Any prior cancer (except basal cell skin cancer) within the past 5 years; Any prior cancer (except basal cell skin cancer) within the past 5 years; Any prior cancer (except basal cell skin cancer) within the past 5 years; Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn); Surgical candidates for recurrent ovarian cancer; History of pelvic or vaginal radiation therapy; Known current synchronous endometrial cancer or hyperplasia; Any current or prior cancer diagnosis (except basal cell or squamous cell skin cancer, non-gyn) within the past 5 years; History of pelvic or vaginal radiation therapy; Known current synchronous endometrial cancer or hyperplasia; Current known pregnancy diagnosis; Current biopsy-proven benign endometrial polyp; Endometrial biopsy/sampling within the preceding 1 month showing benign endometrium; Current known pregnancy diagnosis; Current known pregnancy diagnosis; Current known pregnancy diagnosis; Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia; Undergoing hysterectomy for prolapse without a coexisting known or presumed benign uterine pathologic diagnosis of fibroids, endometriosis, benign endometrial polyps, or adenomyosis; Pap test or cervical biopsy within the past 1 month; Endometrial biopsy or office hysteroscopy within the past 1 month; Current known pregnancy diagnosis; Current biopsy-proven AEH/EIN, cervical, vaginal, or vulvar dysplasia; Criteria met for inclusion in any of the other study cohorts; Known current cervical, vaginal, or vulvar dysplasia; Patients with recurrent OC; Known current cervical, vaginal, or vulvar dysplasia; Current known pregnancy diagnosis.

ClinicalTrials.gov NCT05051722